{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T21:40:49Z","timestamp":1788126049695,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,9,20]],"date-time":"2020-09-20T00:00:00Z","timestamp":1600560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,20]],"date-time":"2020-09-20T00:00:00Z","timestamp":1600560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s11096-020-01143-9","type":"journal-article","created":{"date-parts":[[2020,9,20]],"date-time":"2020-09-20T07:02:42Z","timestamp":1600585362000},"page":"1433-1439","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Risk of developing hypertension after hormone therapy for prostate cancer: a nationwide propensity score-matched longitudinal cohort study"],"prefix":"10.1007","volume":"42","author":[{"given":"Yi-Hsuan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhen-Hao","family":"Jhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Lung","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-I","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Han","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Chih","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Chia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Chin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,20]]},"reference":[{"issue":"6","key":"1143_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"1143_CR2","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/cncr.21642","volume":"106","author":"S Basaria","year":"2006","unstructured":"Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer. 2006;106(3):581\u20138.","journal-title":"Cancer"},{"issue":"27","key":"1143_CR3","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","volume":"24","author":"NL Keating","year":"2006","unstructured":"Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448\u201356.","journal-title":"J Clin Oncol"},{"issue":"24","key":"1143_CR4","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1200\/JCO.2006.05.9741","volume":"24","author":"M Braga-Basaria","year":"2006","unstructured":"Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24(24):3979\u201383.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1143_CR5","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/cncr.23658","volume":"113","author":"CJ Nelson","year":"2008","unstructured":"Nelson CJ, Lee JS, Gamboa MC, Roth AJ. Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer. 2008;113(5):1097\u2013106.","journal-title":"Cancer"},{"issue":"5","key":"1143_CR6","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","volume":"67","author":"PL Nguyen","year":"2015","unstructured":"Nguyen PL, Alibhai SM, Basaria S, D'Amico AV, Kantoff PW, Keating NL, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67(5):825\u201336.","journal-title":"Eur Urol"},{"issue":"6","key":"1143_CR7","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.115.018912","volume":"134","author":"KT Mills","year":"2016","unstructured":"Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134(6):441\u201350.","journal-title":"Circulation"},{"issue":"3","key":"1143_CR8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/jch.12479","volume":"17","author":"NR Campbell","year":"2015","unstructured":"Campbell NR, Lackland DT, Lisheng L, Niebylski ML, Nilsson PM, Zhang XH. Using the Global Burden of Disease study to assist development of nation-specific fact sheets to promote prevention and control of hypertension and reduction in dietary salt: a resource from the World Hypertension League. J Clin Hypertens. (Greenwich Conn). 2015;17(3):165\u20137.","journal-title":"J Clin Hypertens. (Greenwich Conn)"},{"issue":"6 Pt 1","key":"1143_CR9","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1097\/01.ju.0000127740.96006.1a","volume":"171","author":"G Lu-Yao","year":"2004","unstructured":"Lu-Yao G, Stukel TA, Yao SL. Changing patterns in competing causes of death in men with prostate cancer: a population based study. J Urol. 2004;171(6 Pt 1):2285\u201390.","journal-title":"J Urol"},{"issue":"5","key":"1143_CR10","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.eururo.2012.05.025","volume":"62","author":"RL Muller","year":"2012","unstructured":"Muller RL, Gerber L, Moreira DM, Andriole G, Castro-Santamaria R, Freedland SJ. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the reduction by dutasteride of prostate cancer events trial. Eur Urol. 2012;62(5):757\u201364.","journal-title":"Eur Urol"},{"issue":"5","key":"1143_CR11","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.eururo.2018.07.024","volume":"74","author":"EL Watts","year":"2018","unstructured":"Watts EL, Appleby PN, Perez-Cornago A, Bueno-de-Mesquita HB, Chan JM, Chen C, et al. Low free testosterone and prostate cancer risk: a collaborative analysis of 20 prospective studies. Eur Urol. 2018;74(5):585\u201394.","journal-title":"Eur Urol"},{"issue":"3","key":"1143_CR12","doi-asserted-by":"publisher","first-page":"R47","DOI":"10.1530\/JOE-12-0582","volume":"217","author":"DM Kelly","year":"2013","unstructured":"Kelly DM, Jones TH. Testosterone: a vascular hormone in health and disease. J Endocrinol. 2013;217(3):R47\u201371.","journal-title":"J Endocrinol"},{"issue":"10","key":"1143_CR13","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1161\/01.CIR.94.10.2614","volume":"94","author":"TM Chou","year":"1996","unstructured":"Chou TM, Sudhir K, Hutchison SJ, Ko E, Amidon TM, Collins P, et al. Testosterone induces dilation of canine coronary conductance and resistance arteries in vivo. Circulation. 1996;94(10):2614\u20139.","journal-title":"Circulation"},{"issue":"9","key":"1143_CR14","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1210\/jcem.86.9.7851","volume":"86","author":"JC Smith","year":"2001","unstructured":"Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab. 2001;86(9):4261\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1143_CR15","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1042\/cs1040195","volume":"104","author":"F Dockery","year":"2003","unstructured":"Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond). 2003;104(2):195\u2013201.","journal-title":"Clin Sci (Lond)"},{"issue":"4","key":"1143_CR16","doi-asserted-by":"publisher","first-page":"410","DOI":"10.2164\/jandrol.108.006924","volume":"30","author":"F Dockery","year":"2009","unstructured":"Dockery F, Bulpitt CJ, Agarwal S, Vernon C, Rajkumar C. Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. J Androl. 2009;30(4):410\u20135.","journal-title":"J Androl"},{"issue":"2","key":"1143_CR17","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s10147-015-0891-7","volume":"21","author":"R Oka","year":"2016","unstructured":"Oka R, Utsumi T, Endo T, Yano M, Kamijima S, Kamiya N, et al. Effect of androgen deprivation therapy on arterial stiffness and serum lipid profile changes in patients with prostate cancer: a prospective study of initial 6-month follow-up. Int J Clin Oncol. 2016;21(2):389\u201396.","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"1143_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/BF03343805","volume":"24","author":"M Nowicki","year":"2001","unstructured":"Nowicki M, Bryc W, Kokot F. Hormonal regulation of appetite and body mass in patients with advanced prostate cancer treated with combined androgen blockade. J Endocrinol Investig. 2001;24(1):31\u20136.","journal-title":"J Endocrinol Investig"},{"issue":"2","key":"1143_CR19","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.urology.2007.08.035","volume":"71","author":"MR Smith","year":"2008","unstructured":"Smith MR, Lee H, Fallon MA, Nathan DM. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology. 2008;71(2):318\u201322.","journal-title":"Urology"},{"key":"1143_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2017.05.013","volume":"122","author":"G Seravalle","year":"2017","unstructured":"Seravalle G, Grassi G. Obesity and hypertension. Pharmacol Res. 2017;122:1\u20137.","journal-title":"Pharmacol Res"},{"issue":"20","key":"1143_CR21","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1001\/jama.291.20.2441","volume":"291","author":"JF Piccirillo","year":"2004","unstructured":"Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL. Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291(20):2441\u20137.","journal-title":"JAMA"},{"issue":"6","key":"1143_CR22","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1111\/j.1464-410X.2010.09703.x","volume":"107","author":"LP Wallner","year":"2011","unstructured":"Wallner LP, Morgenstern H, McGree ME, Jacobson DJ, St Sauver JL, Jacobsen SJ, et al. The effects of metabolic conditions on prostate cancer incidence over 15\u2009years of follow-up: results from the Olmsted County Study. BJU Int. 2011;107(6):929\u201335.","journal-title":"BJU Int"},{"key":"1143_CR23","doi-asserted-by":"publisher","first-page":"31358","DOI":"10.1038\/srep31358","volume":"6","author":"Z Liang","year":"2016","unstructured":"Liang Z, Xie B, Li J, Wang X, Wang S, Meng S, et al. Hypertension and risk of prostate cancer: a systematic review and meta-analysis. Sci Rep. 2016;6:31358.","journal-title":"Sci Rep"},{"issue":"2","key":"1143_CR24","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/BF03346748","volume":"36","author":"K Esposito","year":"2013","unstructured":"Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Parretta E, et al. Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis. J Endocrinol Investig. 2013;36(2):132\u20139.","journal-title":"J Endocrinol Investig"},{"issue":"4","key":"1143_CR25","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1161\/HYPERTENSIONAHA.111.189258","volume":"59","author":"T Stocks","year":"2012","unstructured":"Stocks T, Van Hemelrijck M, Manjer J, Bjorge T, Ulmer H, Hallmans G, et al. Blood pressure and risk of cancer incidence and mortality in the metabolic syndrome and cancer project. Hypertension. 2012;59(4):802\u201310.","journal-title":"Hypertension"},{"key":"1143_CR26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12885-016-2122-7","volume":"16","author":"SM Berger","year":"2016","unstructured":"Berger SM, Gislason G, Moore LL, Andersson C, Torp-Pedersen C, Denis GV, et al. Associations between metabolic disorders and risk of cancer in Danish men and women\u2013a nationwide cohort study. BMC Cancer. 2016;16:133.","journal-title":"BMC Cancer"},{"issue":"1","key":"1143_CR27","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/HJH.0000000000000770","volume":"34","author":"JL Harding","year":"2016","unstructured":"Harding JL, Sooriyakumaran M, Anstey KJ, Adams R, Balkau B, Brennan-Olsen S, et al. Hypertension, antihypertensive treatment and cancer incidence and mortality: a pooled collaborative analysis of 12 Australian and New Zealand cohorts. J Hypertens. 2016;34(1):149\u201355.","journal-title":"J Hypertens"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-020-01143-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-020-01143-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-020-01143-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,19]],"date-time":"2021-09-19T23:59:32Z","timestamp":1632095972000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-020-01143-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,20]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1143"],"URL":"https:\/\/doi.org\/10.1007\/s11096-020-01143-9","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,20]]},"assertion":[{"value":"20 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}